Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study

Hernandez-Villafuerte, K., Garau, M., Towse, T. and Garrison, L.

Consulting Report
January 2017

Sign Up for OHE Updates

Why not sign up for our email updates? Around once or twice a week we will send you a round-up of the latest news, events and publications from OHE.

I'm already signed up    No thanks

PhRMA commissioned OHE Consulting to explore options and recommend methods that could help middle-income countries efficiently and effectively identify medicines for formulary inclusion.

In a previous publication we presented a framework for developing medicines formularies which combines macro-level decision making factors (focusing on the health system organisation and its priority setting), and micro-level factors (looking at intervention-specific effects) to determine the overall value of medicines (click here to access).

In this report we apply this framework to analyse the Mexican decision making process for the inclusion of a new health treatment in the positive list. We propose a series of recommendations that could improve the efficiency of the Mexican decision making process.